Rezolute (RZLT) Other Non-Current Liabilities (2014 - 2026)
Rezolute recorded quarterly Other Non-Current Liabilities of $483000.0 in Q1 2026, little changed quarter-over-quarter from $483000.0 in Q4 2025, and little changed year-over-year from $483000.0 in Q1 2025.
Rezolute's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $483000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed 0.0% year-over-year to $483000.0; the TTM figure through Mar 2026 stood at $483000.0 (changed 0.0% YoY), while the FY2025 annual figure was $468000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities came in at $483000.0 for Q1 2026 at Rezolute, roughly flat from $483000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $483000.0 in Q3 2024 to a low of $395000.0 in Q1 2022.
- A 5-year average of $450647.1 and a median of $453000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities rose 13.59% in 2024 and changed 0.0% in 2025, its largest moves.
- Rezolute's Other Non-Current Liabilities stood at $434000.0 in 2022, then gained by 1.15% to $439000.0 in 2023, then grew by 8.66% to $477000.0 in 2024, then grew by 1.26% to $483000.0 in 2025, then changed by 0.0% to $483000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $483000.0, $483000.0, and $483000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 477,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | 453,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 412,000.00 |
| Mar 31, 2023 | 447,000.00 |
| Dec 31, 2022 | 434,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 407,000.00 |
| Mar 31, 2022 | 395,000.00 |
| Dec 31, 2021 | 383,000.00 |
| Sep 30, 2021 | 371,000.00 |
| Jun 30, 2021 | 387,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Dec 31, 2019 | 48,000.00 |
| Sep 30, 2019 | 85,000.00 |
| Jun 30, 2019 | 121,000.00 |
| Sep 30, 2018 | 55,000.00 |
| Jun 30, 2018 | 216,000.00 |
| Mar 31, 2018 | 212,358.00 |
| Dec 31, 2017 | 243,686.00 |
| Sep 30, 2017 | 274,130.00 |
| Jun 30, 2017 | 304,575.00 |
| Mar 31, 2017 | 314,655.00 |
| Dec 31, 2016 | 335,588.00 |
| Sep 30, 2016 | 367,813.00 |
| Jun 30, 2016 | 400,038.00 |
| Mar 31, 2016 | 431,341.00 |
| Dec 31, 2015 | 460,794.00 |
| Sep 30, 2015 | 453,586.00 |
| Jun 30, 2015 | 480,490.00 |
| Mar 31, 2015 | 172,809.00 |
| Dec 31, 2014 | 464,040.00 |
| Sep 30, 2014 | 253,068.00 |
| Jun 30, 2014 | 33,881.00 |